Expensive Growth Acquisition! AbbVie Lowers Its Annual Forecast After Billion-Dollar Deal for Apogee!
Reading Time: 3 minutes
Revenue & Profit Above Expectations: AbbVie reports total revenue of $17.0 billion and an EPS of $3.65, surpassing FactSet expectations Growth Drivers Offset Humira Erosion: Skyrizi and Rinvoq shine with gains, compensating for Humira Downgrade Forecast After Billion-Dollar Acquisition: The $10.9 billion acquisition of Apogee Therapeutics weighs on earnings by $0.14 The US biopharmaceutical company AbbVie (ABBV) demonstrated strong operational momentum in Q2 2026, while simultaneously dampening market earnings expectations for the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
